H5N1 News and Research

Latest H5N1 News and Research

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issued its Interim Management Statement covering the period January 1, 2010, to March 31, 2010.

28 May 2010

PuriCore revenue increases 28% to $40.0 million for year ending December 31, 2009

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announced its Final Results for the year ending December 31, 2009, and the availability of its 2009 annual report on its website.

28 May 2010

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

NanoViricides, Inc., has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 20th, in a timely fashion.

24 May 2010

University of Sydney hosts emerging infectious diseases and biosecurity conference

The latest research to combat emerging infectious diseases threatening Australia is being presented at the Sydney Institute of Emerging Infectious Diseases and Biosecurity Conference at the University of Sydney today.

19 May 2010

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010.

18 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

NanoViricides, Inc., announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering. The registered shelf offering became effective on April 29, 2010.

12 May 2010

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

12 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.

28 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Test shows efficacy of avian antibodies against H5N1 and H1N1 influenza in mice

Scientists have discovered for the first time that antibodies in common eggs laid by hens vaccinated against the H5N1 virus can potentially prevent a possible H5N1 pandemic, raising the possibility that the same principle could be applied to the current H1N1 influenza pandemic.

21 Apr 2010

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

Though the world has made "great strides" in eliminating H5N1 (avian flu) from poultry since the "peak of its outbreak in 2006" in 63 countries, the virus persists in Bangladesh, China, Egypt, Indonesia and Vietnam, VOA News reports (DeCapua, 4/16).

20 Apr 2010

WHO discusses shortcomings of its H1N1 response

Keiji Fukuda, the WHO's top influenza expert, on Monday said the organization did not effectively communicate the uncertainties of the H1N1 (swine flu) virus, which led to confusion worldwide, Reuters reports.

15 Apr 2010

H5N1 News and Research

Latest H5N1 News and Research

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

PuriCore revenue increases 28% to $40.0 million for year ending December 31, 2009

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

University of Sydney hosts emerging infectious diseases and biosecurity conference

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

Vical reports net loss of $8.5 million for first-quarter 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Stalk structure of Mx protein restrains components of influenza virus in infected cells

Nanoviricides become registered trademark under USPTO

Test shows efficacy of avian antibodies against H5N1 and H1N1 influenza in mice

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

WHO discusses shortcomings of its H1N1 response

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

H5N1 News and Research

Latest H5N1 News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in